PathAI IPO
PathAI is an artificial intelligence company focused on improving pathology diagnosis and treatment through machine learning technology. The company develops AI-powered tools to help pathologists make more accurate diagnoses and assists pharmaceutical companies in drug development. Investors are interested in the potential for AI to transform medical diagnostics and improve patient outcomes.
Key Facts
| Industry | Digital Health |
| Founded | 2016 |
| Headquarters | Boston, MA |
| Employees | ~400 |
| Website | pathai.com |
| Funding | Series C. Total raised: ~$255M |
About PathAI
PathAI develops artificial intelligence-powered tools for pathology to improve diagnostic accuracy and efficiency. The company's machine learning platform analyzes digitized tissue samples to help pathologists identify diseases, particularly cancer, with greater precision and consistency. PathAI's technology aims to reduce diagnostic errors and variability while accelerating the pathology workflow in hospitals and laboratories.
The company works with pharmaceutical companies, clinical laboratories, and academic medical centers to deploy AI-assisted pathology solutions. PathAI has developed specific applications for various cancer types and has been involved in clinical trials to validate the effectiveness of AI-augmented diagnosis. The platform addresses critical challenges in pathology including pathologist shortages, diagnostic variability, and the increasing complexity of precision medicine requirements that demand more detailed tissue analysis.
IPO Status
PathAI has raised substantial venture capital funding and has been valued at over $1 billion in previous funding rounds, making it a unicorn in the AI healthcare space. The company has partnerships with major pharmaceutical companies and healthcare institutions, but has not announced IPO plans. The AI healthcare market continues to attract significant investment, though the timeline for companies in this space to go public varies widely. PathAI appears focused on expanding its technology capabilities and customer partnerships rather than pursuing immediate public markets, with no confirmed details about IPO preparations or timeline discussions.
Competitors
Frequently Asked Questions
Does PathAI have a stock?
No, PathAI has not had an IPO and remains a private company. There are no confirmed announcements about plans to go public.
When is the PathAI IPO date?
PathAI has not announced an IPO date, and no timeline for going public has been confirmed by the company or its investors.
How can I buy PathAI stock?
You cannot currently buy PathAI stock as it is a private company with no announced IPO plans. The stock would only become available after a public offering is completed.
Stay Updated on the PathAI IPO
Get real-time alerts when PathAI files for an IPO, prices shares, or begins trading.
Get IPO Alerts